How do I start and dose Novolog (insulin aspart) for an adult with type 1 or type 2 diabetes, and what are the storage requirements?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Novolog (Insulin Aspart) Initiation and Dosing

Inject Novolog subcutaneously 5-10 minutes before meals into the abdomen, thigh, buttocks, or upper arm, typically starting at 4 units per meal or 0.1-0.2 units/kg/meal in Type 1 diabetes, or adding 4 units before the largest meal in Type 2 diabetes already on basal insulin. 1

Administration Timing and Technique

  • Inject 5-10 minutes before meals (not 30 minutes like regular insulin) 1
  • Rotate injection sites within the same region to prevent lipodystrophy
  • Never inject into areas of lipodystrophy or localized cutaneous amyloidosis as this causes erratic absorption and hyperglycemia 1
  • Use the shortest needles available (4mm pen needles) as first-line to avoid intramuscular injection 2

Starting Doses by Diabetes Type

Type 1 Diabetes

  • Initiate as part of a basal-bolus regimen with intermediate or long-acting insulin 1
  • Total daily dose typically 0.5-1.0 units/kg/day, with 50% as basal and 50% divided among meals 2
  • Start prandial doses at approximately 4 units per meal or 0.1-0.2 units/kg per meal, adjusting based on carbohydrate intake
  • Increase blood glucose monitoring frequency during initiation 1

Type 2 Diabetes

  • Add Novolog to existing basal insulin when HbA1c ≥7.5% despite optimization 2
  • Start with 4 units before the largest meal 3
  • Titrate by 1-2 units every 3 days based on postprandial glucose readings
  • Continue metformin and other oral agents; do not abruptly discontinue 2
  • Target 2-hour postprandial glucose <180 mg/dL

Dosage Individualization

Individualize based on metabolic needs, blood glucose monitoring, and glycemic goals 1. Adjust for:

  • Changes in physical activity or meal patterns
  • Renal or hepatic dysfunction
  • Acute illness
  • Concomitant medications that affect glucose metabolism 1

Mixing Instructions

Critical mixing rules to prevent dosing errors:

  • May ONLY be mixed with NPH insulin for subcutaneous injection 1
  • When mixing: Draw Novolog first, then NPH, and inject immediately 1
  • Never mix with any other insulin when using an insulin pump 1
  • Never mix with insulin glargine (incompatible pH) 4

Storage Requirements

Unopened Vials/Pens

  • Refrigerate at 2-8°C (36-46°F) until expiration date 1
  • May store at room temperature up to 30°C (86°F) for 28 days 1

In-Use Storage

  • Vials: 28 days at room temperature or refrigerated 1
  • Pens (FlexPen, FlexTouch, PenFill): 28 days at room temperature; do NOT refrigerate once opened 1
  • Insulin pumps: Change reservoir every 7 days maximum; do not expose to temperatures >37°C (98.6°F) 1

Critical Storage Warnings

  • Never freeze; discard if frozen 1
  • Avoid temperatures <2°C or >30°C when not in pump 4, 1
  • Keep spare bottles available 4
  • Inspect before each use: should be clear and colorless; discard if cloudy, discolored, or contains particles 4, 1

Common Pitfalls to Avoid

  1. Lipodystrophy: Repeatedly injecting the same site causes insulin malabsorption and unpredictable glucose control. Strict site rotation is mandatory 1

  2. Timing errors: Injecting too early (>15 minutes before eating) increases hypoglycemia risk; injecting after meals reduces postprandial control 1

  3. Inappropriate mixing: Mixing with long-acting insulins other than NPH causes unpredictable absorption 1

  4. Storage violations: Using insulin exposed to extreme temperatures or past 28 days of opening reduces potency 1, 5

  5. Abrupt discontinuation of oral agents: When adding Novolog to Type 2 regimens, continue metformin to reduce weight gain and insulin requirements 2

Monitoring Requirements

  • Increase blood glucose monitoring frequency during any insulin regimen changes 1
  • Use fasting glucose to titrate basal insulin
  • Use postprandial glucose (2 hours after meals) to titrate Novolog doses 2
  • Monitor for hypoglycemia, especially nocturnal (though Novolog has lower nocturnal hypoglycemia rates than regular insulin) 6, 7

Device-Specific Considerations

  • FlexPen and FlexTouch dial in 1-unit increments 1
  • Never share pens, cartridges, or needles between patients even if needle is changed (bloodborne pathogen risk) 1
  • Remove and discard needle after each injection; store pen without needle attached 1

Related Questions

What is the recommended dosing regimen for Novolog (insulin aspart) FlexPen in adults with type 1 or type 2 diabetes?
After administering 10 units of morning basal insulin, the fasting glucose is 70 mg/dL; what adjustment, if any, should be made to the insulin dose?
In a 50‑year‑old man with blood pressure 130/100 mmHg and a 75‑g oral glucose tolerance test showing fasting glucose 244 mg/dL and 2‑hour glucose 375 mg/dL, what are the appropriate management strategies and medication options if he refuses insulin?
For a 72‑year‑old woman with type 2 diabetes, weight 44 kg, serum creatinine 0.57 mg/dL (eGFR > 90 mL/min/1.73 m²), on prednisone 30 mg daily, currently using NPH insulin 15 U at 08:00 with an insulin‑sensitivity factor of 25 mg/dL per unit and an insulin‑to‑carbohydrate ratio of 10 g per unit, and with glucose readings of 127 mg/dL at 08:00, 364 mg/dL at 13:00 after 80 g carbohydrate, 314 mg/dL at 17:00 after 30 g carbohydrate, and 268 mg/dL at 21:00, what should the NPH insulin dose, insulin‑sensitivity factor, and insulin‑to‑carbohydrate ratio be?
How should I evaluate and manage a 52-year-old female with a 15-year history of type 2 diabetes on premixed insulin (30/70) who presents with generalized body aches, mild dizziness, tachycardia, hypertension, and a random blood glucose of 256 mg/dL?
In a hypovolemic patient with postural orthostatic tachycardia syndrome (POTS), does increased dehydration cause greater heart‑rate increase and variability on standing and worsen gastrointestinal symptoms such as nausea?
What is the next higher oral dose of Wegovy (semaglutide) after the initial 1.5 mg tablet?
What urine output would you expect in a patient with a glomerular filtration rate of 9 mL/min (end‑stage renal disease)?
In a 24-year-old male with mental health disorder, plaque psoriasis, bilateral lower extremity amputations, severe muscle deconditioning, bronchiectasis, protein‑calorie malnutrition, and a QTc of 387 ms who is currently taking escitalopram 10 mg with inadequate response, what are the contraindications to initiating mirtazapine and what is the safest transition plan?
Is dulaglutide (Trulicity) the only GLP‑1 receptor agonist approved for primary prevention of atherosclerotic cardiovascular disease?
What is the recommended frontline therapy for BCR‑ABL‑positive chronic myeloid leukemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.